Combining Lumipulse p-tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease-modifying therapy.

Results demonstrated here are similar to those previously seen with the notable addition that the p‐tau217/Aβ42 ratio; the linear combination of p‐tau217, Aβ42/40 along with age, sex, and APOE ε4; and the composite score all perform significantly better than p‐tau217 alone to predict Aβ PET status (albeit at a nominally significant, uncorrected level) and provide higher accuracies at a range of different sensitivity/specificity cut‐offs.

also in 7,732 other papers